Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer : A qualitative study
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: Prostate cancer is the most common cancer among men in the United States. Treatment guidelines recommend active surveillance for low-risk prostate cancer, which involves monitoring for progression, to avoid or delay definitive treatments and their side effects. Despite increased uptake, adherence to surveillance remains a challenge.
METHODS: We conducted semi-structured, qualitative, virtual interviews based on the Theoretical Domains Framework (TDF), with men (15) who were or had been on active surveillance for their low-risk prostate cancer in 2020. Interviews were transcribed and coded under TDF's behavioral theory-based domains. We analyzed domains related to adherence to surveillance using constructivist grounded theory to identify themes influencing decision processes in adherence.
RESULTS: The TDF domains of emotion, beliefs about consequences, environmental context and resources, and social influences were most relevant to surveillance adherence-. From these four TDF domains, three themes emerged as underlying decision processes: trust in surveillance as treatment, quality of life, and experiences of self and others. Positive perceptions of these three themes supported adherence while negative perceptions contributed to non-adherence (i.e., not receiving follow-up or stopping surveillance). The relationship between the TDF domains and themes provided a theoretical process describing factors impacting active surveillance adherence for men with low-risk prostate cancer.
CONCLUSIONS: Men identified key factors impacting active surveillance adherence that provide opportunities for clinical implementation and practice improvement. Future efforts should focus on multi-level interventions that foster trust in surveillance as treatment, emphasize quality of life benefits and enhance patients' interpersonal experiences while on surveillance to optimize adherence.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Cancer medicine - (2023) vom: 27. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Subramanian, Lalita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Active surveillance |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/cam4.6847 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366425439 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366425439 | ||
| 003 | DE-627 | ||
| 005 | 20240210233026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6847 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM366425439 | ||
| 035 | |a (NLM)38151901 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Subramanian, Lalita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer |b A qualitative study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Prostate cancer is the most common cancer among men in the United States. Treatment guidelines recommend active surveillance for low-risk prostate cancer, which involves monitoring for progression, to avoid or delay definitive treatments and their side effects. Despite increased uptake, adherence to surveillance remains a challenge | ||
| 520 | |a METHODS: We conducted semi-structured, qualitative, virtual interviews based on the Theoretical Domains Framework (TDF), with men (15) who were or had been on active surveillance for their low-risk prostate cancer in 2020. Interviews were transcribed and coded under TDF's behavioral theory-based domains. We analyzed domains related to adherence to surveillance using constructivist grounded theory to identify themes influencing decision processes in adherence | ||
| 520 | |a RESULTS: The TDF domains of emotion, beliefs about consequences, environmental context and resources, and social influences were most relevant to surveillance adherence-. From these four TDF domains, three themes emerged as underlying decision processes: trust in surveillance as treatment, quality of life, and experiences of self and others. Positive perceptions of these three themes supported adherence while negative perceptions contributed to non-adherence (i.e., not receiving follow-up or stopping surveillance). The relationship between the TDF domains and themes provided a theoretical process describing factors impacting active surveillance adherence for men with low-risk prostate cancer | ||
| 520 | |a CONCLUSIONS: Men identified key factors impacting active surveillance adherence that provide opportunities for clinical implementation and practice improvement. Future efforts should focus on multi-level interventions that foster trust in surveillance as treatment, emphasize quality of life benefits and enhance patients' interpersonal experiences while on surveillance to optimize adherence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a active surveillance | |
| 650 | 4 | |a primary care physicians | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a trust | |
| 650 | 4 | |a urologists | |
| 700 | 1 | |a Hawley, Sarah T |e verfasserin |4 aut | |
| 700 | 1 | |a Skolarus, Ted A |e verfasserin |4 aut | |
| 700 | 1 | |a Rankin, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Fetters, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Witzke, Karla |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Radhakrishnan, Archana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g (2023) vom: 27. Dez. |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:27 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6847 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 27 |c 12 | ||